Genzyme Prices MS Drug Aubagio At Discount To Established Therapies
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approved Aubagio for patients with relapsing forms of multiple sclerosis on Sept. 12. Sponsor Genzyme, owned by Sanofi, announced an annual price of $45,000 for the drug, below the only other oral therapy for MS, Novartis’ Gilenya.
You may also be interested in...
Lemtrada A Game Changer In MS, Genzyme Researchers Say
The paradigm shift long-lasting Lemtrada will excite, along with Aubagio’s gains since its launch in October, put Sanofi well on the road to its goal of multiple sclerosis leadership, Genzyme research execs say.
Investors See Pharma Promise In 2013, Look Past Patent Cliff
The pharma sector has been on an upswing in the public markets for the last few years. Looking at the sector from fundamental and technical perspectives, Wall Street remains optimistic that pharmaceutical stocks can continue to perform for at least the next few years.
Teva CEO Offers Small Insights Into Big Priorities As Run Up to Dec. 11
Teva CEO Jeremy Levin provided additional glimpses of the company’s new strategy on a Q3 earnings call in advance of an investor meeting on Dec. 11, where he and Teva management will reveal their full agenda. Levin again put the emphasis on “focus” and “discipline” over “pure growth,” confirmed the company’s ‘confidence in the MS drug laquinimod, and highlighted several senior management appointments that reflect Teva’s new priorities.